Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.
The Cabilly patents are two US patents issued to Genentech and City of Hope which relate to the "fundamental technology required for the artificial synthesis of antibody molecules." [ 1 ] The name refers to lead inventor Shmuel Cabilly, who was awarded the patent while working at City of Hope in the 1980s. [ 2 ]
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). [4] A Phase I clinical trial found that it was well tolerated by healthy subjects. [5]
The implant was approved by the U.S. health regulator in 2021 to treat a chronic disorder that caused blurred vision. The following year, Genentech voluntarily recalled the implant following test ...
Pages in category "Drugs developed by Genentech" The following 102 pages are in this category, out of 102 total. This list may not reflect recent changes. A.
The company also selectively out licenses limited use of its technology to other companies. Companies licensing ImmunoGen's technology include Amgen, Bayer HealthCare, Biotest, Genentech/Roche, Eli Lilly, Novartis, Sanofi, and Takeda. [9] Roche's Kadcyla (ado-trastuzumab emtansine) utilizes ImmunoGen's ADC technology. It has been approved and ...
Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue. The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in ...
Pages in category "Genentech" The following 2 pages are in this category, out of 2 total. This list may not reflect recent changes. ...